Ten-year clinical laboratory follow-up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of predominant rheumatic etiology
Flavio Tarasoutchi, MD*,*,
Max Grinberg, MD*,
Guilherme S. Spina, MD*,
Roney O. Sampaio, MD*,
L. uís F. Cardoso, MD*,
Eduardo G. Rossi, MD*,
Pablo Pomerantzeff, MD*,
Francisco Laurindo, MD*,
Protásio L. da Luz, MD, FACC* and
José Antônio F. Ramires, MD, FACC*
* Instituto do Coração, (InCor), University of São Paulo School of Medicine, Valvular Hear Disease Unit, São Paulo, Brazil
View larger version (21K):
[in a new window]
|
Figure 1 Clinical evolution of the 75 patients throughout the study, including outcomes.
|
|
View larger version (11K):
[in a new window]
|
Figure 2 Survival of the groups over the years. The survival was 100% in the asymptomatic group and 82% in the symptomatic group.
|
|
View larger version (24K):
[in a new window]
|
Figure 3 Evolution of left ventricular end-systolic diameter, left ventricular end-diastolic diameter, shortening fraction, left ventricular ejection fraction (LVEF), and percentile variation of the rest-exercise ejection fraction in the symptomatic group and asymptomatic group over time. For symptomatic group, four years follow-up was preoperative phase.
|
|
|
